Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand

Background: A multi-criteria decision analysis (MCDA) approach has been suggested for helping purchasers in low- and middle-income countries in an evidence-based assessment of multi-source pharmaceuticals to mitigate potential adverse consequences of price-based decisions on patient access to effect...

Full description

Bibliographic Details
Main Authors: Apinchonbancha, N. (Author), Assamawakin, A. (Author), Holtorf, A.-P (Author), Indrianti, R. (Author), Kristin, E. (Author), Upakdee, N. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04243nam a2200529Ia 4500
001 10.1186-s40545-021-00333-8
008 220427s2021 CNT 000 0 und d
020 |a 20523211 (ISSN) 
245 1 0 |a Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand 
260 0 |b BioMed Central Ltd  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s40545-021-00333-8 
520 3 |a Background: A multi-criteria decision analysis (MCDA) approach has been suggested for helping purchasers in low- and middle-income countries in an evidence-based assessment of multi-source pharmaceuticals to mitigate potential adverse consequences of price-based decisions on patient access to effective medicines. Six workshops for developing MCDA-instruments for purchasing were conducted in Indonesia, Kazakhstan, Thailand, and Kuwait in 2017–2020. In Indonesia and Thailand, two pilot-initiatives aimed to implement the instruments for hospital drug purchasing decisions. Objective: By analysing and comparing the experiences and progress from the MCDA-workshops and the two case-examples for hospital implementation in Indonesia and Thailand, we aim to gain insights, which will support future implementation. Methods: The selection of criteria and their average weight were compared quantitatively across the MCDA-instruments developed in all four countries and settings. Implementation experiences from two case-examples were studied, which included (1) testing the instrument across a variety of drugs in seven hospitals in Thailand and (2) implementation in one specialty hospital in Indonesia. Semi-structured interviews were conducted via web-conferences with four diverse stakeholders in the pilot implementation projects in Thailand and Indonesia. The open responses were evaluated through qualitative content analysis and synthesis using grounded theory coding. Results: Drivers for implementation were making ‘better’ decisions, achieving transparency and a rational selection process, reducing drug shortages, and assuring consistent quality. Challenges were seen on the technical level (definition or of criteria, scoring methods, access to data) or change-related challenges (resistance, perception of increased workload, lack of competencies or capabilities, lack of resources). The comparison of the MCDA instruments revealed high similarity, but also clear need for local adaptations in each specific case. Conclusion: A set a of measures targeting challenges related to utility, methodology, data requirements, capacity building and training as well as the broader societal impact can help to overcome challenges in the implementation. Careful planning of implementation and organizational change is recommended for ensuring commitment and fit to local context and culture. Designing a collaborative change program for each application of MCDA-based purchasing will enable healthcare stakeholders to maximally benefit in terms of quality and effectiveness of care and access for patients. © 2021, The Author(s). 
650 0 4 |a Article 
650 0 4 |a case study 
650 0 4 |a content analysis 
650 0 4 |a controlled study 
650 0 4 |a decision making 
650 0 4 |a female 
650 0 4 |a grounded theory 
650 0 4 |a hospital 
650 0 4 |a Hospital formulary 
650 0 4 |a Hospital pharmacy 
650 0 4 |a human 
650 0 4 |a Implementation 
650 0 4 |a Indonesia 
650 0 4 |a LMICs 
650 0 4 |a Low- and middle-income countries 
650 0 4 |a MCDA 
650 0 4 |a multicriteria decision analysis 
650 0 4 |a Multi-criteria decision analysis 
650 0 4 |a Multi-source pharmaceuticals 
650 0 4 |a purchasing 
650 0 4 |a Purchasing 
650 0 4 |a qualitative analysis 
650 0 4 |a questionnaire 
650 0 4 |a scoring system 
650 0 4 |a semi structured interview 
650 0 4 |a Tender selection 
650 0 4 |a Thailand 
650 0 4 |a workload 
700 1 |a Apinchonbancha, N.  |e author 
700 1 |a Assamawakin, A.  |e author 
700 1 |a Holtorf, A.-P.  |e author 
700 1 |a Indrianti, R.  |e author 
700 1 |a Kristin, E.  |e author 
700 1 |a Upakdee, N.  |e author 
773 |t Journal of Pharmaceutical Policy and Practice